Novartis keeps firms waiting for results of global panel review

Premium content

This article is only available to Premium subscribers of The Lawyer. Premium subscribers benefit from accessing all of our award-winning online content including interviews, commentary, analysis and in-depth research.

View our subscription options

Register now to The Lawyer to access our latest news stories, read selected briefings from key firms and gain essential careers insight to help you make the most of your current and future roles.

Contact Us: if you have any questions regarding your subscription, call us on +44 (0)20 7292 3716 or email us at customerservices@thelawyer.com

View our subscription options

Having problems?

Contact us on +44 (0)20 7292 3716 | email: customerservices@thelawyer.com

If you are looking for our Jobs site, please click here 

Latest Briefings

Jersey Investment Funds – Regulatory options

Jersey is long established as a primary centre for the establishment of offshore funds and has been at the forefront of international developments, which have attracted international sponsors, promoters, fund managers, advisors and investors. One of the key features of Jersey’s fund industry is the flexibility and range of structures and corresponding regulatory and commercial […]

Firewall and Forum clauses – What protection is available when foreign courts seek to intervene

By Rachael Reynolds, Deborah Barker Roye Trustees can all too easily find themselves caught up in litigation in another jurisdiction given the increasingly international nature of offshore trusts. The firewall regime and forum for administration clauses within deeds, when robustly applied and upheld by the Courts, are the key to ensuring questions concerning a trust […]

In the data protection crosshairs: New legislation in North Macedonia

After more than two years of preparations, public debates and consultations between different stakeholders, the Parliament of North Macedonia passed the new Law on Personal Data Protection (“Law”) on 16 February 2020. This game-changing piece of legislation introduces the GDPR in the local regulatory framework and it is already in force as of 24 February […]

Risk management: The digital transformation in the health industry

By Jahmiah Ferdinand-Hodkin, Samaneh Frounchi As the health industry migrates from paper-based to electronic clinical records, the risks associated with the collection, use and disclosure of personal health information changes. The requirements for electronic document security, encryption and transmission come to the forefront. The use of electronic repositories opens the door for cyberattacks and significant […]

Gender reassignment in the workplace and pension issues

By Liz Wood, Siobhan Bishop Gender reassignment in the workplace is a complex issue which requires careful and sensitive handling by employers. Liz Wood and Siobhan Bishop discuss who is protected, examples of discrimination, Gender Recognition certificates and how to calculate pension entitlement. Siobhan Bishop: Hello and welcome to our podcast where we’re covering gender […]

Recommended

Novartis

Macfarlanes leads as Novartis moves HQ to London

Macfarlanes is advising on Novartis’s HQ move to White City, as the Swiss drugs giant sets its sights on joining a cluster of life sciences companies in West London. Novartis’s 600 HQ staff will relocate from Frimley in Surrey to the WestWorks building on the White City Place campus within the UK’s “golden triangle” bioscience hub […]

/h/y/s/novartis_317.jpg

Hogan Lovells wins the top role for Novartis in $9bn pharma deal

Hogan Lovells and Cravath Swaine & Moore have won the top roles on Novartis’ $9bn purchase of Chicago-based gene therapy company AveXis. The deal, in which the Swiss pharmaceutical giant is offering $218 per share for AveXis, is being led by Hogan Lovells Washington DC-based corporate transactions partner Joseph Gilligan who is advising Novartis. He is working alongside New […]

Blood

A&O, Osborne Clarke and Proskauer Rose advise on $1.7bn Novartis deal

Allen & Overy (A&O), Osborne Clarke (OC) and Proskauer Rose have taken mandates advising on the $1.7bn (£1bn) sale of Swiss pharmaceutical giant Novartis’ transfusion diagnostics unit to Spanish plasma therapies company Grifols. Barcelona-headquartered Grifols will acquire the transfusion diagnostics unit of Novartis for US$1,675bn (£1,04bn). The assets include medical products and technology, as well […]

/h/y/s/novartis_317.jpg
1

Novartis unveils panel designed to build ‘long-term partnerships’

Novartis has announced the results of its first panel review since the company’s $40bn takeover of Alcon, with three magic circle firms – Allen & Overy, Freshfields Bruckhaus Deringer and Linklaters – securing spots on the global roster along with two US firms. Pharma company Novartis’s new panel, called the legal preferred firm programme, is […]

Recruit legal talent

Get your role in front of over 300,000 legal professionals when you advertise with The Lawyer. Our team of experts provide bespoke solutions to help solve all your recruitment challenges.

Find out more

Register now to The Lawyer to access our latest news stories, read selected briefings from key firms and gain essential careers insight to help you make the most of your current and future roles.

Contact Us: if you have any questions regarding your subscription, call us on +44 (0)20 7292 3716 or email us at customerservices@thelawyer.com

View our subscription options

Having problems?

Contact us on +44 (0)20 7292 3716 | email: customerservices@thelawyer.com

If you are looking for our Jobs site, please click here